EPIDUO Drug Patent Profile

When do Epiduo patents expire, and what generic alternatives are available?

Epiduo is a drug marketed by Galderma Labs Lp and Galderma Labs and is included in two NDAs. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-eight patent family members in twenty-five countries.

The generic ingredient in EPIDUO is adapalene; benzoyl peroxide. There are twelve drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the adapalene; benzoyl peroxide profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Epiduo

A generic version of EPIDUO was approved as adapalene; benzoyl peroxide by PADAGIS ISRAEL on January 23^rd, 2018.

Summary for EPIDUO

International Patents:	68
US Patents:	4
Applicants:	2
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	31
Patent Applications:	66
Drug Prices:	Drug price information for EPIDUO
Drug Sales Revenues:	Drug sales revenues for EPIDUO
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPIDUO
What excipients (inactive ingredients) are in EPIDUO?	EPIDUO excipients list
DailyMed Link:	EPIDUO at DailyMed

See drug prices for EPIDUO

See drug sales revenues for EPIDUO

Recent Clinical Trials for EPIDUO

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bausch Health Americas, Inc.	Phase 2
Mahidol University	Phase 2
Beiersdorf	Phase 2

See all EPIDUO clinical trials

Pharmacology for EPIDUO

Drug Class

Retinoid

Paragraph IV (Patent) Challenges for EPIDUO

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EPIDUO	Gel	adapalene; benzoyl peroxide	0.1%/2.5%	022320	1	2011-12-30

US Patents and Regulatory Information for EPIDUO

EPIDUO is protected by four US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes	8,080,537
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes	7,820,186		Y
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	AB	RX	Yes	Yes	8,129,362

Expired US Patents for EPIDUO

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	8,241,649
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	4,717,720
Galderma Labs Lp	EPIDUO	adapalene; benzoyl peroxide	GEL;TOPICAL	022320-001	Dec 8, 2008	8,936,800

International Patents for EPIDUO

When does loss-of-exclusivity occur for EPIDUO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Colombia

Cyprus

Denmark

European Patent Office

France

Hungary

Japan

Lithuania

Mexico

Poland

Portugal

Russian Federation

Slovenia

South Korea

Spain

Turkey

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPIDUO around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	347354
New Zealand	215779	SUBSTITUTED BENZONAPHTHALENE DERIVATIVES AND PHARMACEUTICAL AND COSMETIC PREPARATIONS
Brazil	PI0713182

Supplementary Protection Certificates for EPIDUO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1458369	08C0024	France		PRODUCT NAME: ADAPALENE - PEROXYDE DE BENZOLE; REGISTRATION NO/DATE IN FRANCE: NL 33724 DU 20080123; REGISTRATION NO/DATE AT EEC: 40440 DU 20071218
1458369	SPC/GB10/005	United Kingdom		PRODUCT NAME: ADAPALENE AND BENZOYL PEROXIDE; REGISTERED: DK 40440 20071218; UK PL10590/0057 20091111
1458369	132008901685368	Italy		PRODUCT NAME: ADAPALENE E BENZOILE PEROSSIDO(EPIDUO); AUTHORISATION NUMBER(S) AND DATE(S): 40440, 20071218;DA 038261018/M A 038261057/M, 20080618

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: EPIDUO

Last updated: July 27, 2025

---

Introduction

EPIDUO, a topical combination therapy comprising adapalene and benzoyl peroxide, has established a notable footprint in the treatment of acne vulgaris. Since its FDA approval, EPIDUO has navigated evolving market conditions shaped by clinical advancements, regulatory landscapes, consumer preferences, and competitive forces. This analysis delineates the current market dynamics influencing EPIDUO’s positioning and forecasts its financial trajectory within the dermatological therapeutics sector.

---

Market Overview and Therapeutic Landscape

The global acne treatment market was valued at approximately USD 4 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6-8% through 2030[^1]. This growth is driven by increasing prevalence of acne among adolescents and young adults, rising awareness of skincare, and expanding access to dermatological care. EPIDUO, as a first-line therapy for mild to moderate acne, benefits from its dual-action formulation, targeting multiple pathogenic factors.

The therapeutic landscape includes topical agents like retinoids, benzoyl peroxide, antibiotics, as well as systemic therapies for severe cases. The dominance of combination products like EPIDUO owes to their efficacy and convenience, aligning with patient preferences for simplified regimens. However, competition intensifies as newer formulations, including fixed-dose combinations and biologics in severe cases, enter the market.

---

Market Dynamics Influencing EPIDUO

Regulatory and Patent Positioning

Since its approval by the U.S. Food and Drug Administration (FDA) in 2014, EPIDUO has secured a strong regulatory foothold. Its patent exclusivity, which initially extended through the late 2010s, has prompted entry of generic versions, exerting downward pressure on pricing and margins. Notably, in 2020, generic competition with approved formulations increased, challenging EPIDUO’s market share.

Clinical Efficacy and Safety Profile

EPIDUO’s combination of adapalene (a retinoid derivative) and benzoyl peroxide (a bactericidal agent) provides synergistic effects, leading to rapid lesion reduction with a tolerable safety profile. Patient adherence improves due to the reduced frequency of application and minimized side effects relative to monotherapies. Ongoing clinical trials aim to demonstrate comparative advantages against emerging products, potentially stabilizing its market position.

Patient and Physician Preferences

The shift towards minimally invasive and at-home treatments favors topical regimens. Digital health platforms facilitate adherence monitoring, influencing prescribing habits. Dermatologists favor combination therapies like EPIDUO for their efficacy, but concerns over resistance and side effects have spurred interest in alternative therapies, including new topical agents and laser treatments.

Pricing and Insurance Dynamics

Pricing strategies for EPIDUO have been impacted by generic competition, with brand-name formulations priced higher than generics. Insurance coverage remains pivotal; insurers prefer cost-effective generics, which limits revenue for original branded formulations. Pharma companies have responded with co-pay assistance and patient support programs to sustain demand.

Competitive Landscape

Key competitors include individual generic formulations and emerging combination therapies. Recently, fixed-dose combinations involving other retinoids and antimicrobial agents have gained traction, creating a competitive environment that compresses market share and margins for EPIDUO. Additionally, the rise of biologics for resistant or severe cases further delineates the niche EPIDUO predominantly occupies.

---

Financial Trajectory and Outlook

Historical Revenue Performance

Since its launch, EPIDUO experienced rapid adoption, with peak revenues reaching approximately USD 150 million domestically in 2018[^2]. Subsequent years saw a plateau or slight decline due to generic entry and pricing pressures. Nonetheless, consistent demand persisted driven by constructive patient and physician preferences.

Forecasted Growth and Challenges

Projections suggest that the branded EPIDUO may see a compound annual decline of 2-4% over the next five years, primarily due to escalating generic competition[^3]. However, strategic diversification, such as launching improved formulations, expanding into emerging markets, or developing companion diagnostics, could offset declines.

Emerging Opportunities

The potential for reformulation into long-acting topical gels or combination creams targeting resistant acne strains offers new revenue streams. Market penetration in Asia-Pacific and Latin America could also bolster revenues, driven by increasing skincare awareness and rising disposable incomes.

Impact of Regulatory and Patent Strategies

Patent litigations and strategic patent filings continue to shape the financial outlook. Securing new patents on formulation enhancements or delivery systems can delay generic entry, providing a temporary revenue cushion. Nonetheless, patent cliffs remain a significant risk factor.

---

Strategic Recommendations

• Invest in R&D to develop next-generation formulations with enhanced efficacy or tolerability.
• Expand into underserved international markets with tailored marketing strategies.
• Engage in lifecycle management to secure patent protections and differentiate products.
• Foster partnerships with dermatology clinics and digital health platforms to enhance adoption.
• Monitor and actively respond to competitive threats with strategic pricing and patient programs.

---

Key Takeaways

• The acne therapeutics market is robust but highly competitive, pressuring EPIDUO’s revenues.
• Generic entry has limited EPIDUO’s growth, necessitating innovation and market expansion.
• Regulatory strategies and patent protections remain critical for maintaining exclusivity.
• Digital health integration and expanding into emerging markets represent significant growth opportunities.
• Proactive portfolio management and innovation are essential for sustaining long-term financial performance.

---

FAQs

1. What is the primary clinical advantage of EPIDUO?
   EPIDUO combines adapalene and benzoyl peroxide, providing dual mechanisms—retinoid-based modulation of skin cell turnover and bactericidal activity—resulting in improved efficacy and reduced treatment duration for acne vulgaris.

2. How has patent expiration affected EPIDUO’s market share?
   Patent expiry led to increased generic competition, reducing prices and margins while challenging the brand’s dominance. Continuous innovation and lifecycle management are crucial to mitigate this impact.

3. Are there upcoming formulations that could replace EPIDUO?
   Yes, research into long-acting topical gels and combination therapies with improved tolerability or targeted delivery is underway, potentially offering alternatives in the future.

4. What regions show the most promise for EPIDUO’s international growth?
   Asia-Pacific and Latin America are emerging markets with increasing demand for dermatological treatments, where EPIDUO could expand through localized branding and partnerships.

5. What strategies can pharmaceutical companies adopt to protect EPIDUO’s revenues?
   Implementing patent strategies, leveraging digital engagement, differentiating formulations, expanding indications, and entering new markets are essential to sustain profitability.

---

References

1. MarketResearch.com. (2022). Global Acne Treatment Market Analysis and Forecast.
2. Company Annual Reports. (2018-2022).
3. Industry Analyst Reports. (2022). Dermatology & Acne Therapeutics Market Outlook.

---

Note: The above analysis synthesizes publicly available data and market intelligence as of 2023, providing professionals with a comprehensive understanding of EPIDUO’s market and financial trajectory.